Cargando…

Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo

BACKGROUND: Cardiovascular-MR (CMR) is the gold standard for quantifying myocardial infarction using late gadolinium enhancement (LGE) technique. Both 2D- and 3D-LGE-sequences are used in clinical practise and in clinical and experimental studies for infarct quantification. Therefore the aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Jablonowski, Robert, Nordlund, David, Kanski, Mikael, Ubachs, Joey, Koul, Sasha, Heiberg, Einar, Engblom, Henrik, Erlinge, David, Arheden, Håkan, Carlsson, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029523/
https://www.ncbi.nlm.nih.gov/pubmed/24308673
http://dx.doi.org/10.1186/1471-2261-13-110
_version_ 1782317222800130048
author Jablonowski, Robert
Nordlund, David
Kanski, Mikael
Ubachs, Joey
Koul, Sasha
Heiberg, Einar
Engblom, Henrik
Erlinge, David
Arheden, Håkan
Carlsson, Marcus
author_facet Jablonowski, Robert
Nordlund, David
Kanski, Mikael
Ubachs, Joey
Koul, Sasha
Heiberg, Einar
Engblom, Henrik
Erlinge, David
Arheden, Håkan
Carlsson, Marcus
author_sort Jablonowski, Robert
collection PubMed
description BACKGROUND: Cardiovascular-MR (CMR) is the gold standard for quantifying myocardial infarction using late gadolinium enhancement (LGE) technique. Both 2D- and 3D-LGE-sequences are used in clinical practise and in clinical and experimental studies for infarct quantification. Therefore the aim of this study was to investigate if image acquisitions with 2D- and 3D-LGE show the same infarct size in patients and ex vivo. METHODS: Twenty-six patients with previous myocardial infarction who underwent a CMR scan were included. Images were acquired 10-20 minutes after an injection of 0.2 mmol/kg gadolinium-based contrast agent. Two LGE-sequences, 3D-inversion recovery (IR) and 2D-phase-sensitive (PS) IR, were used in all patients to quantify infarction size. Furthermore, six pigs with reperfused infarction in the left anterior descending artery (40 minutes occlusion and 4 hours of reperfusion) were scanned with 2D- and 3D-LGE ex vivo. A high resolution T1-sequence was used as reference for the infarct quantification ex vivo. Spearman’s rank-order correlation, Wilcoxon matched pairs test and bias according to Bland-Altman was used for comparison of infarct size with different LGE-sequences. RESULTS: There was no significant difference between the 2D- and 3D-LGE sequence in left ventricular mass (LVM) (2D: 115 ± 25 g; 3D: 117 ± 24 g: p = 0.35). Infarct size in vivo using 2D- and 3D-LGE showed high correlation and low bias for both LGE-sequences both in absolute volume of infarct (r = 0.97, bias 0.47 ± 2.1 ml) and infarct size as part of LVM (r = 0.94, bias 0.16 ± 2.0%). The 2D- and 3D-LGE-sequences ex vivo correlated well (r = 0.93, bias 0.67 ± 2.4%) for infarct size as part of the LVM. The IR LGE-sequences overestimated infarct size as part of the LVM ex vivo compared to the high resolution T1-sequence (bias 6.7 ± 3.0%, 7.3 ± 2.7% for 2D-PSIR and 3D-IR respectively, p < 0.05 for both). CONCLUSIONS: Infarct quantification with 2D- and 3D-LGE gives similar results in vivo with a very low bias. IR LGE-sequences optimized for in vivo use yield an overestimation of infarct size when used ex vivo.
format Online
Article
Text
id pubmed-4029523
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40295232014-05-22 Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo Jablonowski, Robert Nordlund, David Kanski, Mikael Ubachs, Joey Koul, Sasha Heiberg, Einar Engblom, Henrik Erlinge, David Arheden, Håkan Carlsson, Marcus BMC Cardiovasc Disord Research Article BACKGROUND: Cardiovascular-MR (CMR) is the gold standard for quantifying myocardial infarction using late gadolinium enhancement (LGE) technique. Both 2D- and 3D-LGE-sequences are used in clinical practise and in clinical and experimental studies for infarct quantification. Therefore the aim of this study was to investigate if image acquisitions with 2D- and 3D-LGE show the same infarct size in patients and ex vivo. METHODS: Twenty-six patients with previous myocardial infarction who underwent a CMR scan were included. Images were acquired 10-20 minutes after an injection of 0.2 mmol/kg gadolinium-based contrast agent. Two LGE-sequences, 3D-inversion recovery (IR) and 2D-phase-sensitive (PS) IR, were used in all patients to quantify infarction size. Furthermore, six pigs with reperfused infarction in the left anterior descending artery (40 minutes occlusion and 4 hours of reperfusion) were scanned with 2D- and 3D-LGE ex vivo. A high resolution T1-sequence was used as reference for the infarct quantification ex vivo. Spearman’s rank-order correlation, Wilcoxon matched pairs test and bias according to Bland-Altman was used for comparison of infarct size with different LGE-sequences. RESULTS: There was no significant difference between the 2D- and 3D-LGE sequence in left ventricular mass (LVM) (2D: 115 ± 25 g; 3D: 117 ± 24 g: p = 0.35). Infarct size in vivo using 2D- and 3D-LGE showed high correlation and low bias for both LGE-sequences both in absolute volume of infarct (r = 0.97, bias 0.47 ± 2.1 ml) and infarct size as part of LVM (r = 0.94, bias 0.16 ± 2.0%). The 2D- and 3D-LGE-sequences ex vivo correlated well (r = 0.93, bias 0.67 ± 2.4%) for infarct size as part of the LVM. The IR LGE-sequences overestimated infarct size as part of the LVM ex vivo compared to the high resolution T1-sequence (bias 6.7 ± 3.0%, 7.3 ± 2.7% for 2D-PSIR and 3D-IR respectively, p < 0.05 for both). CONCLUSIONS: Infarct quantification with 2D- and 3D-LGE gives similar results in vivo with a very low bias. IR LGE-sequences optimized for in vivo use yield an overestimation of infarct size when used ex vivo. BioMed Central 2013-12-05 /pmc/articles/PMC4029523/ /pubmed/24308673 http://dx.doi.org/10.1186/1471-2261-13-110 Text en Copyright © 2013 Jablonowski et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jablonowski, Robert
Nordlund, David
Kanski, Mikael
Ubachs, Joey
Koul, Sasha
Heiberg, Einar
Engblom, Henrik
Erlinge, David
Arheden, Håkan
Carlsson, Marcus
Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo
title Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo
title_full Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo
title_fullStr Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo
title_full_unstemmed Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo
title_short Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo
title_sort infarct quantification using 3d inversion recovery and 2d phase sensitive inversion recovery; validation in patients and ex vivo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029523/
https://www.ncbi.nlm.nih.gov/pubmed/24308673
http://dx.doi.org/10.1186/1471-2261-13-110
work_keys_str_mv AT jablonowskirobert infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo
AT nordlunddavid infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo
AT kanskimikael infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo
AT ubachsjoey infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo
AT koulsasha infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo
AT heibergeinar infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo
AT engblomhenrik infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo
AT erlingedavid infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo
AT arhedenhakan infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo
AT carlssonmarcus infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo